News Jounce elopes with Concentra, leaving Redx at the altar A $425 million proposed marriage between Redx Pharma of the UK and Jounce Ther
News Concentra gatecrashes Jounce and Redx’ merger party Biotech interloper is led by Kevin Tang of Tang Capital management, which owns 10% of Jounce.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.